3.07
Schlusskurs vom Vortag:
$3.07
Offen:
$3.09
24-Stunden-Volumen:
527.63K
Relative Volume:
0.64
Marktkapitalisierung:
$424.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.44M
KGV:
-8.7714
EPS:
-0.35
Netto-Cashflow:
$-42.28M
1W Leistung:
+3.02%
1M Leistung:
+27.92%
6M Leistung:
+18.99%
1J Leistung:
+207.00%
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie CMPX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CMPX
Compass Therapeutics Inc
|
3.07 | 412.08M | 0 | -45.44M | -42.28M | -0.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-01 | Fortgesetzt | Raymond James | Outperform |
2025-04-02 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2025-02-24 | Eingeleitet | Guggenheim | Buy |
2025-02-19 | Eingeleitet | Piper Sandler | Overweight |
2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2023-01-31 | Eingeleitet | Jefferies | Buy |
2023-01-27 | Eingeleitet | Stifel | Buy |
2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
2021-12-22 | Eingeleitet | Raymond James | Outperform |
2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
What drives Compass Therapeutics Inc. stock priceFast-track wealth growth - Autocar Professional
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline - Insider Monkey
What analysts say about Compass Therapeutics Inc. stockBreakthrough wealth creation - jammulinksnews.com
Is Compass Therapeutics Inc. a good long term investmentRemarkable growth - jammulinksnews.com
Compass Therapeutics Inc. Stock Analysis and ForecastUnmatched profit potential - Autocar Professional
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
Is Compass Therapeutics Inc. stock a growth or value playHigh Return Setup Scanner - beatles.ru
What analysts say about Compass Therapeutics Inc. stock outlookFree Real-Time Market Predictions - beatles.ru
What makes Compass Therapeutics Inc. stock price move sharply10x Return With Managed Risk - Newser
Why Compass Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
How Axsome Therapeutics Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
How Compass Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Stifel reiterates Buy rating on Compass Therapeutics stock with $11 target - Investing.com Canada
Contrasting Compass Therapeutics (NASDAQ:CMPX) & Generation Bio (NASDAQ:GBIO) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Buy” by Brokerages - Defense World
Compass Therapeutics (CMPX) soars 4.01% on FDA Fast Track Designation - AInvest
Vontobel Holding Ltd. Invests $57,000 in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Earn Buy Rating - AInvest
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Raymond James Financial - Defense World
H.C. Wainwright Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics, Inc.(NasdaqCM: CMPX) added to Russell 3000E Growth Index - MarketScreener
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer - TipRanks
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Benzinga
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 48,021 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Confirms Directors at Annual Meeting - TipRanks
Cholangiocarcinoma Market Booming Worldwide, Estimated to Reach USD 2,334.4 Mn by 2032 | Incyte CorporationSOUTHEAST - SOUTHEAST - NEWS CHANNEL NEBRASKA
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | - GuruFocus
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | CMPX Stock News - GuruFocus
Two Sigma Advisers LP Cuts Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Transition Metals (CVE:XTM) Shares Up 62.5% – Time to Buy? - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
BNP Paribas Financial Markets Makes New $27,000 Investment in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
ProShare Advisors LLC Has $42,000 Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):